SAN FRANCISCO – Medicines360, a nonprofit, global women’s health pharmaceutical company with a mission of expanding access to quality medicines, was awarded the Clinical Trial Result of the Year at the 2019 Clinical and Research Excellence (CARE) Awards. The CARE Awards celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing new and needed medicines to market.
Medicines360 was recognized for its ACCESS IUS (A Comprehensive Contraceptive Efficacy and Safety Study of an IUS) trial, the largest ongoing Phase 3 clinical trial of an intrauterine system (IUS or IUD) in the United States. The ACCESS IUS trial is carried out in a large, diverse cohort of women, providing excellent representation of the U.S. female population, including women of all races, ages 16 to 45, those who have and have not given birth, as well as women with a range of body mass indexes (BMIs). As the largest ongoing Phase 3 clinical trial of an intrauterine system (IUS or IUD) in the country, our trial was recognized for delivering broadly applicable results from a highly patient-centered trial that help debunk outdated myths hampering U.S. provider and patient IUD use, and help women receive better reproductive healthcare.
“It is an honor to be recognized for our work studying and providing women effective medicines that enable them to live their best and fullest lives,” said Andrea Olariu, M.D., Ph.D., chief operating officer of Medicines360. “We work hard to ensure our products are evaluated in robust clinical trials that reflect real-world populations. This award is validation that our inclusive approach is helping ensure more medicines meet the diverse needs of all women.”
The CARE Awards celebrate achievements across the spectrum of key R&D activities, from successes in early and late-stage research, to advances in technological tools, to innovations in trial design and execution. The full list of categories and CARE Awards winners can be found here.
ABOUT MEDICINES360
Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance coverage, or geographic location. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.
ABOUT INFORMA PHARMA INTELLIGENCE
Trusted by over 3,000 of the world’s leading pharmaceutical companies, CROs, med and biotech organizations, and healthcare service providers, the Pharma Intelligence suite of intelligence solutions delivers vital, accurate, and timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world. At Pharma Intelligence, global teams of subject area experts follow and analyze key diseases, clinical trials, drug approvals and R&D activities as part of the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
MEDIA CONTACT
Andrea Fetchko
Direct: (202) 591-4015
E-mail: Afetchko@jpa.com
